S&P TEST

SWOT & PESTLE.com

CSL LIMITED (COMMONWEALTH SERUM LABORATORIES) SWOT & PESTLE ANALYSIS

© Barakaat Consulting - An Ezzy IT Consulting Business

This is a licensed product and is not to be photocopied or distributed. All rights reserved. Unauthorized reproduction is strictly prohibited. Research is based on best available materials and resources. Topurchase reprints of this document, please email support@swotandpestle.com.



Company Name : CSL Limited (Commonwealth Serum Laboratories)

Company Sector : Biotechnology

Operating Geography : Australia, Global

About the Company: CSL - Commonwealth Serum Laboratories, is a specialty biotechnology company operating globally. It researches, develops, manufactures, and then markets products that are used to treat and prevent serious human medical conditions. It was established in 1916 in Australia to serve the health needs of a nation isolated by war. But over the years CSL has kept innovating and provided Australians with access to advanced medical services, some of which include insulin, penicillin, and vaccines against influenza, polio, and other infectious diseases. CSL Limited was incorporated in 1991 and was listed in 1994. The major product area of CSL includes blood plasma derivatives, vaccines, antivenoms, and cell culture reagents used in research and manufacturing applications. It has its headquarters in Melbourne, Australia, and

provides life-saving medicines to more than 100 nations. CSL has also acquired several companies. Decades of research, investigation, innovation, and experience make CSL the global innovative leader. As of 2023, it employed more than 30,000 employees globally.

Innovation is the core of CSL and remains its USP. It enjoys a reputation as a passionate yet responsible organization driven to care for patients and deliver on its commitments. CSL's mission reads "Driven by Our Promise". Its values include "Patient Focus", "Innovation", "Integrity", "Collaboration" and "Superior Performance".

Revenue:

\$13,310 million – FY ending 30th June 2023 (y-o-y growth of 26%)

\$10,562 million – FY ending 30th June 2022



SWOT Analysis:

The SWOT Analysis for CSL Limited (Commonwealth Serum Laboratories) is given below:

Strengths	Weaknesses
1. CSL's well-established market leadership	1. Heavy reliance on plasma supply can impact
gives it a significant competitive edge	business operations
2. Well diverse performing product portfolio	2. Complex manufacturing processes may lead
boosts profitability	to supply chain issues.
3. A strong focus on research and development	
fuels the company's sustainable growth	
4. Globally acknowledged leading innovation	
of Seqirus will strengthen its market position	
5. Building efficiency and scale of its	
operations to supply the expanding global	
market will boost its market share	
market will boost its market share Opportunities	Threats
	Threats 1. Strong competition from pharmaceutical
Opportunities	
Opportunities 1. The evolving influenza vaccine market will	1. Strong competition from pharmaceutical
Opportunities 1. The evolving influenza vaccine market will boost CSL's product sales	1. Strong competition from pharmaceutical and biotechnology companies can impact
Opportunities 1. The evolving influenza vaccine market will boost CSL's product sales 2. Expanding immunoglobin market will	1. Strong competition from pharmaceutical and biotechnology companies can impact profitability
Opportunities 1. The evolving influenza vaccine market will boost CSL's product sales 2. Expanding immunoglobin market will enable CSL to drive high growth	 Strong competition from pharmaceutical and biotechnology companies can impact profitability Privacy and cybersecurity issues related to
Opportunities 1. The evolving influenza vaccine market will boost CSL's product sales 2. Expanding immunoglobin market will enable CSL to drive high growth 3. Global collaborations for innovation will	 Strong competition from pharmaceutical and biotechnology companies can impact profitability Privacy and cybersecurity issues related to patient, donor, and employee data can severely
Opportunities 1. The evolving influenza vaccine market will boost CSL's product sales 2. Expanding immunoglobin market will enable CSL to drive high growth 3. Global collaborations for innovation will strengthen its product portfolio	 Strong competition from pharmaceutical and biotechnology companies can impact profitability Privacy and cybersecurity issues related to patient, donor, and employee data can severely



PESTLE Analysis:

The PESTLE Analysis for CSL Limited (Commonwealth Serum Laboratories) is given below:

Political	Economical
 The Australian government's increasing support of biosimilar medicines will impact CSL's product line The Australian government's scheme to provide twice the medication for the cost of one prescription will pressure CSL's supply chain 	 Foreign exchange and interest rate fluctuations will impact CSL's operational costs Raw material shortage and price hikes will impact CSL's production costs
Social	Technological
 Increased use of telehealth services will allow CSL to reach a larger patient base Consumers increasingly opting for personalized medicine will influence the company's product portfolio 	 Leveraging data science to strengthen its R&D and optimizing its processes to positively impact the business Use of artificial intelligence for better efficiency and growth A strong focus on digitalization will provide a competitive advantage
Legal	Environmental
 A lawsuit against CSL Group for gender discrimination can damage its reputation. Compliance with patient safety and product quality will impact operational costs Changing Global laws and regulations in the healthcare industry will severely impact CSL's supply chain. 	 A strong focus on environmental sustainability will positively impact CSL's brand reputation CSL's focus on reducing the amount of packaging materials used will optimize its operations

Please note that our free summary reports contain the SWOT and PESTLE table contents only.

The complete report for **CSL Limited (Commonwealth Serum Laboratories)** SWOT & PESTLE Analysis is a paid report at **19.53 U.S.D.**



* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."

S&P SWOT & PESTLE.com

SWOT & PESTLE.com is a leading strategy research portal covering detailed Strengths, Weaknesses, Opportunities, Threats (SWOT) and Political, Economic, Social, Technological, Legal and Environmental (PESTLE) analysis of leading industry sectors and organizations across the globe. Our full and comprehensive collection on SWOT and PESTLE has been written by our team of professional analysts consisting of MBA's, CFA's and industry experts. Our analysis has helped businesses, researchers and scholars with valuable insights to make strategic decisions and take their research forward.

We at SWOT & PESTLE.com aim to aid the understanding of the multifaceted business world by presenting a list of diverse companies from across the globe. Business organizations today cannot function in ways that ignore the surroundings that they are set in. SWOT & PESTLE.com makes a keen observation into this aspect and accounts for factors affecting such businesses.

Copyright Notice

The information provided in the SWOT and PESTLE research reports on www.swotandpestle.com are from publicly available documents and sources which are deemed reliable. Further the reports contain analysis and views from the SWOT & PESTLE.com research and analyst team which consists of qualified experts. While every attempt has been made to ensure completeness, accuracy and reliability of the analysis, Barakaat Consulting and its associate websites cannot be held responsible or legal liable for omissions or errors in our reports or on any of our pages.

(C)2024 Barakaat Consulting. All rights reserved. This report may not be reproduced, copied or redistributed, in whole or in part, in any form or by any means, without the express written consent of Barakaat Consulting. Also, Barakaat Consulting is the sole copyright owner of this report, and any use of this report by any third party is strictly prohibited without a license expressly granted by Barakaat Consulting. Neither all nor any part of the contents of this report, or any opinions expressed herein, can be used in advertising, press releases, or promotional materials without prior written approval from Barakaat Consulting. Any violation of Barakaat Consultings rights in this report will be executed to the fullest extent of the law, including the pursuit of monetary damages and injunctive relief in the event of any breach of the foregoing restrictions.

Client Support: support@swotandpestle.com